Cytek Biosciences (NASDAQ:CTKB) Shares Down 3% Following Insider Selling
Cytek Biosciences (NASDAQ:CTKB) Shares Down 3% Following Insider Selling
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating)'s stock price was down 3% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $10.32 and last traded at $10.48. Approximately 826 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 792,675 shares. The stock had previously closed at $10.80.
赛特克生物科技股份有限公司(纳斯达克代码：CTKB-GET Rating)周三股价下跌3%，此前一名内部人士抛售了该公司股票。该公司股价最低跌至10.32美元，最新报10.48美元。午盘交易中，约有826股股票易手，较792,675股的日均成交量下跌100%。该股此前收盘报10.80美元。
Specifically, CFO Patrik Jeanmonod sold 3,500 shares of the firm's stock in a transaction that occurred on Monday, October 24th. The shares were sold at an average price of $15.16, for a total transaction of $53,060.00. Following the completion of the sale, the chief financial officer now owns 85,563 shares of the company's stock, valued at approximately $1,297,135.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CTO Ming Yan sold 20,000 shares of Cytek Biosciences stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $14.42, for a total transaction of $288,400.00. Following the sale, the chief technology officer now directly owns 8,005,624 shares in the company, valued at approximately $115,441,098.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock in a transaction on Monday, October 24th. The stock was sold at an average price of $15.16, for a total value of $53,060.00. Following the sale, the chief financial officer now owns 85,563 shares in the company, valued at $1,297,135.08. The disclosure for this sale can be found here. Insiders sold a total of 146,500 shares of company stock valued at $1,907,145 in the last quarter. 15.90% of the stock is currently owned by company insiders.
具体来说，首席财务官Patrik Jeanmonod在10月24日星期一的一次交易中出售了3500股该公司的股票。这些股票以15.16美元的平均价格出售，总成交额为53,060.00美元。出售完成后，首席财务官现在拥有该公司85563股股票，价值约1297135.08美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过这个环节。其他消息，CTO严明在10月19日星期三的一次交易中出售了20,000股Cytek Biosciences股票。该股以14.42美元的平均价格出售，总成交金额为288,400.00美元。出售后，首席技术官现在直接拥有该公司8,005,624股，价值约115,441,098.08美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在美国证券交易委员会网站。此外，首席财务官Patrik Jeanmonod在10月24日(星期一)的一次交易中出售了3500股Cytek Biosciences股票。股票以15.16美元的平均价格出售，总价值为53,060.00美元。出售后，首席财务官现在拥有该公司85,563股，价值1,297,135.08美元。关于这次销售的披露可以找到这里。上个季度，内部人士总共出售了146,500股公司股票，价值1,907,145美元。15.90%的股份目前由公司内部人士持有。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, Piper Sandler lifted their target price on Cytek Biosciences from $16.00 to $18.00 in a report on Monday, November 14th.
另外，派珀·桑德勒在11月14日周一的一份报告中将Cytek Biosciences的目标价从16.00美元上调至18.00美元。
Cytek Biosciences Stock Down 0.2 %
Cytek Biosciences股价下跌0.2%
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.01). Cytek Biosciences had a negative net margin of 0.47% and a positive return on equity of 0.94%. The company had revenue of $40.48 million during the quarter, compared to the consensus estimate of $43.36 million. As a group, sell-side analysts forecast that Cytek Biosciences, Inc. will post 0.04 earnings per share for the current fiscal year.
赛特克生物科学公司(纳斯达克代码：CTKB-GET Rating)上一次公布季度收益数据是在11月9日星期三。该公司公布本季度每股收益为0.01美元，低于普遍预期的0.02美元(0.01美元)。Cytek Biosciences的净利润率为负0.47%，股本回报率为0.94%。该公司本季度营收为4,048万美元，而普遍预期为4,336万美元。卖方分析师预计，Cytek Biosciences，Inc.本财年的每股收益将为0.04美元。
Institutional Trading of Cytek Biosciences
赛特克生物科学的制度性交易
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its holdings in shares of Cytek Biosciences by 20.1% during the third quarter. Bank of New York Mellon Corp now owns 394,034 shares of the company's stock valued at $5,800,000 after acquiring an additional 66,045 shares in the last quarter. Advisory Research Inc. bought a new position in shares of Cytek Biosciences during the third quarter valued at approximately $614,000. State Street Corp raised its holdings in shares of Cytek Biosciences by 17.6% during the third quarter. State Street Corp now owns 2,030,253 shares of the company's stock valued at $29,885,000 after acquiring an additional 304,433 shares in the last quarter. Algert Global LLC raised its holdings in shares of Cytek Biosciences by 116.5% during the third quarter. Algert Global LLC now owns 46,055 shares of the company's stock valued at $678,000 after acquiring an additional 24,785 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in shares of Cytek Biosciences by 9.2% during the third quarter. UBS Asset Management Americas Inc. now owns 69,822 shares of the company's stock valued at $1,028,000 after acquiring an additional 5,865 shares in the last quarter. Institutional investors own 49.48% of the company's stock.
几家对冲基金和其他机构投资者最近买卖了该股的股票。纽约梅隆银行(Bank Of New York Mellon Corp)第三季度增持Cytek Biosciences股票20.1%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有394,034股该公司股票，价值5,800,000美元，此前该公司在上一季度增持了66,045股。咨询研究公司在第三季度购买了价值约614,000美元的Cytek Biosciences股票的新头寸。道富集团在第三季度增持了Cytek Biosciences的股票17.6%。道富银行目前持有该公司2,030,253股股票，价值29,885,000美元，上一季度又收购了304,433股。阿尔盖特全球有限责任公司在第三季度将其持有的赛特克生物科学公司的股票增加了116.5%。Alert Global LLC在上个季度增持了24,785股后，现在拥有46,055股该公司股票，价值678,000美元。最后，瑞银资产管理美洲公司(UBS Asset Management America Inc.)在第三季度将其持有的Cytek Biosciences股票增加了9.2%。瑞银资产管理美洲公司(UBS Asset Management America Inc.)目前持有69,822股该公司股票，价值1,028,000美元，此前该公司在上个季度增持了5,865股。机构投资者持有该公司49.48%的股份。
About Cytek Biosciences
关于赛特克生物科学公司
(Get Rating)
(获取评级)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家细胞分析解决方案公司，提供细胞分析工具，促进生物医学研究和临床应用的科学进步。它提供极光和北极光系统，这是一种光谱流动细胞仪，通过利用来自多个激光的荧光信号来区分单个细胞上的荧光标记来提供细胞分析；以及极光细胞分选系统，它利用全光谱图谱技术进一步拓宽了细胞分析的潜在应用。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
- 免费获取StockNews.com关于Cytek生物科学的研究报告(CTKB)
- 好时为什么是一只甜蜜的衰退股票
- 亚马逊股票是否会在2023年为投资者提供服务？
- 分析师将货运情绪转回远期
- 各机构预订波音航班
- 两家生物技术公司在其流水线中以单一产品掀起波澜
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cytek Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。